Takeda Announces Its Certification in Select Group of Global Top Employers® 2018
Takeda Pharmaceutical Company Limited (TOKYO: 4502), (“Takeda”) today announced it has become part of a select group of only thirteen (13) companies and one of two pharmaceuticals to receive global Top Employer® status for 2018. Established over 25 years ago, award certification is given annually by the Top Employers Institute to companies with exceptional employee offerings. The program is organized and designed by the Institute to recognize those that create optimal conditions for their employees to develop professionally and personally, and that achieve the highest standards of excellence for their people.
To be certified globally at least 20 countries, four regions and the applicant company’s global headquarters all needed to be certified by the Top Employer Institute, which Takeda has achieved this year.
“We’d like to thank the Top Employers Institute for recognizing Takeda for the corporate culture we have created,” commented David Osborne, Takeda’s Global Human Resources Officer. “Our focus on patients, combined with our values to act with Integrity, Fairness, Honesty and Perseverance, create a dynamic environment that our people feel strongly about and in which they are empowered to shine.”
The Top Employers Institute assesses company offerings to their employees. It covers 600 HR practices across the following areas:
- Talent Strategy
- Workforce Planning
- Learning & Development
- Performance Management
- Leadership Development
- Career & Succession Management
- Compensation & Benefits
“Takeda really stands out as a global Top Employer for its commitment to people development,” said David Plink, CEO of the Top Employers Institute. “The learning opportunities provided, which enhance the employee journey and are centered on enabling employees to reach their personal professional goals, are first-class and a real differentiator.”
Takeda met the tough requirements of the Top Employers Institute, receiving accreditation in more than 20 countries and regions, across four geographic areas, namely:
- Asia Pacific: Australia, China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand
- Europe: Ireland, Russia, Spain, Turkey and Ukraine
- Latin America: Argentina, Brazil, Colombia, Ecuador, Mexico, Peru and Venezuela
- North America: Canada and United States
- South Africa
“At Takeda, we are passionate about providing the right environment so
our people can learn and progress their careers,” said David Osborne.
“We endeavor to provide diverse learning opportunities across more than
70 countries through programs at institutions such as Oxford University,
Massachusetts Institute of Technology (MIT), Wharton and INSEAD, as well
as by establishing mentoring relationships with our most senior leaders.”
To learn more about the Top Employers Institute and the Top Employers certification visit http://www.top-employers.com.
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas, plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/.
Takeda’s Values & People
Takeda is building a patient-centric and customer-centric organization based on Our Values; always act upon Takeda-ism (Integrity, Fairness, Honesty and Perseverance) and do everything in the order of the four priorities of Patient-Trust-Reputation-Business. We put the patients first and foremost, and through that, we build trust with society, which solidifies our reputation, and that finally can lead to our business performance. These are deeply ingrained in our ways of working. They ensure our commitment to quality and that we do the right thing - at all times.
Our local organizations and people are empowered to respond in the best way to customer needs, and have the possibility to develop and thrive in a diverse and agile organization.
Takeda leaders demonstrate strategic thinking, find innovative ways to serve patients, build trust with society, reinforce our reputation, and grow the business. They create an environment that inspires and enables people to collaborate and move the organization forward. They focus on our few designated priorities and deliver superior results. And they elevate the capabilities of our organization now and for the future.
Takeda: Empowering Our People to Shine
Working at Takeda, it is important that our people feel empowered to perform to the very best of their ability as they work towards creating a brighter future for millions of patients worldwide. We enable all our people to grow, providing support and training where needed, and fostering a culture of trust to allow leadership at all levels.
Media outside Japan:
Takeda Pharmaceutical Company Limited
Vince Docherty, +65 8332 4233
Takeda Pharmaceutical Company Limited
Rebecca Northridge, +65 9457 6037
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 3 3278 2095
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i